OmniAb, Inc.

Equities

OABI

US68218J1034

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:38:44 2024-04-29 pm EDT			5-day change	1st Jan Change
4.555 ^USD	+1.67%		-2.19%	-25.81%

Mar. 25	OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing	MT
Mar. 21	Sector Update: Health Care Stocks Gain Pre-Bell Thursday	MT

OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 20, 2024 at 04:20 pm EDT

OmniAb, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 4.82 million compared to USD 35.35 million a year ago. Net loss was USD 14.05 million compared to net income of USD 6.82 million a year ago.

Basic loss per share from continuing operations was USD 0.14 compared to basic earnings per share from continuing operations of USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to diluted earnings per share from continuing operations of USD 0.07 a year ago.

Latest news about OmniAb, Inc.

OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing	Mar. 25	MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	Mar. 21	MT
OmniAb Swings to Q4 Loss, Revenue Declines	Mar. 20	MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M	Mar. 20	MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index	Dec. 18	CI
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference	Dec. 14	CI
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing	Dec. 13	MT
RBC Initiates OmniAb at Outperform With $6 Price Target, Says Stock Gives Exposure to Growth Potential of Monoclonal Antibody Therapies	Nov. 29	MT
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing	Nov. 13	MT
Transcript : OmniAb, Inc. - Special Call	Nov. 09
OmniAb, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $5.5M, vs. Street Est of $10.3M	Nov. 09	MT
Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee	Nov. 01	CI
A Collaborative Scientific Team Led by Researchers At the Applied Biomedical Science Institute, Scripps Research, Kansas State University, University of Louisville, Omniab, Inc., and Ligand Pharmaceuticals Discovers and Validates Potential New Class of Therapeutic Agent Based on the Unique Antigen Binding Regions of Cow Antibodies	23-09-20	CI
Insider Buy: Omniab	23-08-15	MT
OmniAb, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : OmniAb, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (OABI) OMNIAB Posts Q2 Revenue $6.9M, vs. Street Est of $11.9M	23-08-10	MT
Omniab Announces the Passing of Director Sunil Patel	23-08-07	CI
Hillstream Expands Collaboration With Minotaur, License Deal With OmniAb to Develop Cancer Treatments; Shares Rise	23-07-20	MT
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 3000E Index	23-06-23	CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell Microcap Index	23-06-23	CI
OmniAb, Inc.(NasdaqGM:OABI) dropped from Russell 2500 Growth Index	23-06-23	CI

Chart OmniAb, Inc.

Duration

Period

More charts

Company Profile

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OmniAb, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.48 USD

Average target price

10 USD

Spread / Average Target

+123.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OMNIAB, INC.	-25.81%	527M
IQVIA HOLDINGS INC.	+2.53%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.07%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+6.91%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.83%	18.12B
MEDPACE HOLDINGS, INC.	+30.49%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.05%	11.76B
UNITED THERAPEUTICS CORPORATION	+9.17%	11B

Other Biotechnology & Medical Research